MedTrace Logo

Tranexamic Acid (TXA) in Hip Arthroscopy

NCT05710146 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-02-02

No results posted yet for this study

Summary

The primary goal of this study will be to determine if perioperative IV Tranexamic Acid (TXA) administration will reduce intra-operative bleeding and subsequently improve visual clarity during surgery and reduce operative traction time in patients undergoing hip arthroscopy. Additionally, this study aims to determine whether IV TXA injections will reduce post-operative pain and affect hip-specific patient-reported outcomes in patients undergoing hip arthroscopy.

Conditions

  • Hip Pain Chronic
  • Hip Impingement Syndrome
  • Hip Injuries
  • Blood Loss
  • Femoro Acetabular Impingement

Interventions

DRUG

Tranexamic acid

1 injection of 15mg/kg of TXA in 100mL of normal saline

DRUG

Placebo

1 injection of 100mL of normal saline

Sponsors & Collaborators

Principal Investigators

  • Vehniah K Tjong, MD · Northwestern Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2024-03-31
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05710146 on ClinicalTrials.gov